Citations

Clear

140 citation(s) found for "Barker, R L".

Impact of Cardiomyopathy and Arrhythmia Genetic Testing on Clinical Management Decisions
Morales, Ana , Ting, Yi‐Lee , Bucknor, Brianna, Chahal, C. Anwar A. , Judge, Daniel P. , Owens, Anjali , Wang, Jessica , Alkhayat, Mohamad, Barker, Naomi, Betts, Megan , Chowns, Jessica, Eberly, Rebecca M, Hoffman‐Andrews, Lily , Koduri, Ajit, Padmanabhan, Arun , Wojciak, Julianne , Higgs, Emily , Judge, Daniel P , Owens, Anjali T , Wang, Jessica , Alkhayat, Mohamad , Barker, Naomi , Betts, Megan , Esplin, Edward D , Hoffman-Andrews, Lily , Nair, Ajith P , Padmanabhan, Arun , Vedantham, Vasanth , Wojciak, Julianne , McNally, Elizabeth M , Chahal, Choudhary Anwar A , Morales, Ana , Bucknor, Brianna A., Chowns, Jessica L., Eberly, Rebecca, Higgs, Emily , Huth, Emily A. , Koduri, Ajit , Nair, Ajith, Esplin, Edward D. , McNally, Elizabeth M.

Mayo Clinic

No container title available | July 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.22.26358740 | PMID 42619823 Get It

ABSTRACT Background Genetic testing for cardiomyopathy and arrhythmia (CM/ARRH) provides diagnostic information and informs screening for at-risk relatives. Clinical guidelines recommend genetic testing for these conditions; however, data on how genetic test results influence clinical management recommendations are limited. Here, we determined the frequency of cardiologist-recommended management changes for patients following CM/ARRH genetic testing. Methods This was a retrospective cross-sectional study of patients referred for multigene panel testing between April 2016 and April 2024. Genetically-experienced cardiologists at multicenter academic clinical practices were recruited for participation to complete surveys indicating clinical decision making on patients who had genetic testing. Cases for review were randomly selected to have both positive and non-positive results. Results Among 249 patients (138 positive, 111 non-positive), 136 (54.6%) received clinical management recommendations for their own or their at-risk relatives’ care. Of these, 75 (55.1%) received recommendations for the patient’s own care, most frequently additional diagnostic tests/procedures (n=33). Compared to non-positive results, patients with positive results were more likely to receive recommendations for their own management (66/138, 47.8% vs 9/111, 8.1%; P<0.00001). Patients with positive results in arrhythmogenic cardiomyopathy genes had 263% higher odds of recommended management changes compared to those with TTN (OR=3.63, CI:1.40-9.84, P=0.009). Conclusions The results from CM/ARRH genetic testing on affected patients influenced cardiologists’ medical decision making and management recommendations. Additional research is needed to evaluate how genetic testing for CM/ARRH impact health outcomes.
Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma
Kassamali, Bina , Schoenfeld, Jonathan D., Sethi, Rosh, Bakst, R H, Barker, C. A., Bradford, Carol R., Carr, David R., Chandra, Sunandana , Connolly, Karen L., Demer, Addison M. , Doonan, Bently, Emerick, Kevin, Friedman, Ben J. , Gali, Linna L., Galloway, Thomas J., Geiger, Jessica L., Kohen, Laurie, Koyfman, Shlomo, Kumar, Shweta Sharat, Learned, Kim O. , Leitenberger, Justin J., Lilley, Elizabeth J. , Lukens, John N. , Medina, Theresa , Mitra, Devarati , Ozog, David, Pashtan, Itai, Pham, Nancy , Powers, Molly, Srivastava, Divya, Taylor, Charlotte S., Witek, Matthew E. , Wysong, Ashley, Zander, David, Silk, Ann W., Jambusaria-Pahlajani, Anokhi, Ruiz, Emily S., Chen, Michelle , Kumar, Shweta S. , Schoenfeld, Jonathan D. , Barker, Christopher A. , Bhatt, Alok A. , Bradford, Carol R. , Bunch, Paul M. , Carr, David R., Carucci, John A. , Chen, Michelle , Connolly, Karen , Doonan, Bently P. , Emerick, Kevin S. , Friedman, Ben J. , Galloway, Thomas J. , Guenette, Jeffrey P. , Kelly, Hillary R. , Khushalani, Nikhil I. , Kohen, Laurie Linden, Leitenberger, Justin J. , Medina, Theresa M. , Pashtan, Itai , Patel, Vishal Anil , Srivastava, Divya , Swiecicki, Paul Loren , Wysong, Ashley, Silk, Ann Willman , Jambusaria‐Pahlajani, Anokhi , Ruiz, Emily S.

Mayo Clinic

JAMA Dermatology | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamadermatol.2026.2163 | PMID 42418212 Get It

Importance There is no consensus on staging and surveillance imaging for cutaneous squamous cell carcinoma (CSCC). Although imaging has been shown to affect management, broad recommendations from the National Comprehensive Cancer Network have led to variability in clinical practice. Objective To develop multidisciplinary consensus recommendations on the use of staging and surveillance imaging of localized CSCC. Evidence Review A multidisciplinary expert panel across academic and clinical practice settings convened a Delphi consensus, with 3 iterative survey rounds from January to June 2025. Data were analyzed from February 2025 to January 2026. Eligibility defined by at least 1 to 2 CSCC publications during the previous 5 years, involvement in a relevant clinical trial, experience treating at least 3 patients monthly with CSCC, and/or 5 years or longer of clinical practice. Fifty-four experts were invited and 45 (83%) completed all 3 rounds and were included in the final analysis. Structured Delphi surveys evaluated clinical scenarios, imaging modalities, and surveillance strategies for CSCC. Consensus and near-consensus recommendations were generated, defined as 80% or greater and 70% to 79% agreement, respectively. Findings The 45 participants (21 female individuals [47%] and 24 male individuals [53%]; 14 Asian individuals [31%], 1 multiracial individual [2%], and 30 White individuals [67%]) consisted of dermatology (15 [33%]), medical oncology (7 [16%]), radiation oncology (9 [20%]), radiology (9 [20%]), surgery (3 [7%]), and otolaryngology specialists (2 [4%]). The Delphi panel recommended staging and surveillance for CSCCs with at least a 15% risk of metastasis. Consensus or near consensus was reached to recommend staging and surveillance imaging for tumors with a concern for metastasis, bone invasion, invasion beyond subcutaneous fat, large-caliber nerve invasion, or a diameter of 4 cm or larger or the combination of tumors with poorly differentiated histology and any of the following: diameter of 2 cm or larger, lymphovascular invasion and subcutaneous fat invasion, or lymphovascular invasion and small-caliber perineural invasion. Computed tomography imaging was the preferred modality for nodal staging (38 [84%]) and surveillance (35 [78%]). For surveillance duration, consensus was reached to provide imaging for at least 2 years, and near consensus was reached for at least 3 years. Conclusions and Relevance This study provides an expert consensus–based framework to standardize imaging in localized CSCC that may inform future guidelines.
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Johnson, Douglas, Albertini, Mark R. , Barker, C. A., Bateni, Sarah, Baumgartner, Joel, Bichakjian, Christopher, Boland, Genevieve , Chandra, Sunandana , Chen, David, Choi, Jacob, DiMaio, Dominick, Dronca, Roxana, Fleming, Martin D. , Galan, Anjela , Guild, Samantha, Hu-Lieskovan, Siwen, Karakousis, Giorgos, Kendra, Kari, Kiuru, Maija, Lange, Julie R., Lanning, Ryan, Logan, Theodore, Materin, Miguel, Nelson, Kelly, Olson, Daniel, Pa, Ott, Puzanov, Igor, Rothermel, Luke, Salama, April K., Shannon, Adrienne, Singh, Arun, Stacey, Andrew, Tsai, Katy, Wuthrick, Evan, Xing, Yan, McMillian, Nicole, Espinosa, Sara, Swetter, Susan M. , Johnson, Douglas B., Barker, Christopher A. , Baumgartner, Joel , Bhatia, Shailender , Bichakjian, Christopher K. , Chmielowski, Bartosz , DiMaio, Dominick J. , Guild, Samantha, Hu‐Lieskovan, Siwen , Karakousis, Giorgos C. , Kiuru, Maija H. , Lanning, Ryan M. , Logan, Theodore F. , Materin, Miguel Angel , Nelson, Kelly C., Olson, Daniel , Olszanski, Anthony J. , Puzanov, Igor , Rothermel, Luke D. , Salama, April K.S. , Sharma, Rohit , Wuthrick, Evan , McMillian, Nicole R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 15, 2026 | Volume: 24 | Issue: 6 | Pages: 272-277

10.6004/jnccn.2026.0027 | PMID 42297031 Get It

The NCCN Guidelines for Melanoma: Cutaneous provide strategies for the diagnosis, treatment, and follow-up of patients with cutaneous melanoma, which is among the most common cancers in the United States. The outcome of cutaneous melanoma is significantly influenced by stage at initial presentation. Generally, localized disease and smaller primary tumors have been associated with more favorable prognosis. Thus, the select content featured in this issue focuses on risk factors associated with cutaneous melanoma development and which should be considered during an initial assessment. These include (1) phenotypic predispositions, (2) personal medical history or comorbidities, (3) genetic predispositions, and (4) environmental factors.
Real-world use of artificial intelligence for automated prognostication and systemic therapeutic decision making in localized RCC.
Barker, Kenneth, Humayun, Muhammad Abdullah, Tahir, Haris Bin, Ayub, Umair , Barker, Kenneth N. , Tahir, Haris Bin , Riaz, Irbaz Bin

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e16502 Get It

e16502 Background: Accurate postoperative risk stratification in localized clear-cell renal cell carcinoma (ccRCC) informs prognosis, surveillance intensity, and eligibility for adjuvant systemic therapy. Although validated prognostic models (Leibovich 2018, SSIGN, and UISS) exist, they are inconsistently applied in routine practice due to workflow and documentation barriers. Using AI assisted tools within the electronic medical record (EMR) may enable rapid, standardized risk assessment and improve clinical use. Methods: We retrospectively analyzed 92 patients with localized ccRCC undergoing radical nephrectomy and postoperative oncology evaluation (December 2021–September 2025) across three Mayo Clinic sites. Pathology reports and oncology notes were extracted via structured SQL queries. Clinical and pathologic variables were parsed using a zero-shot GPT-4o pipeline. Gold-standard prognostic risk classification and adjuvant therapy eligibility were established by an expert oncology clinician using validated prognostic calculators and KEYNOTE-564 eligibility criteria. AI-generated outputs and novice manual abstraction by two first-year fellows were compared against expert assessment using accuracy, precision, recall, and F1 score. Leibovich and SSIGN were evaluated as three-class models (low/intermediate/high), and UISS as binary risk stratification (high vs non-high). Results: Among 92 patients with localized ccRCC (median age 64 years [range 41–78]), AI-generated outputs demonstrated near-perfect agreement with expert assessment for KEYNOTE-564 adjuvant immunotherapy eligibility (accuracy 97%, precision 100%, recall 97%, F1 score 98%). For three-class prognostic stratification, AI achieved perfect agreement for Leibovich disease-free survival risk (accuracy, precision, recall, and F1 all 100%), outperforming novice abstraction. For SSIGN, AI demonstrated strong multi-class performance (accuracy 91%, precision 91%, recall 93%, F1 score 92%), compared with novice abstraction (accuracy 92%, F1 score 90%). For binary UISS risk stratification, AI achieved 81% accuracy, precision 74%, recall 100%, and F1 score 85% showing a tendency towards false positives. Conclusions: This study demonstrates AI can use existing prognostic and systemic therapy eligibility to accurately risk stratify and identify patients eligible for adjuvant systemic immunotherapy post nephrectomy. For our next steps, we plan to develop a multimodal AI platform integrating pathologic, radiologic, and clinical data to improve prognostication for outcomes and predictive capabilities for patients who would benefit from adjuvant systemic therapy for more personalized medicine.
Ontogeny and Natural History of Therapy‐Related Clonal Hematopoiesis From a Multidisciplinary CHIP Clinic
Patel, Shyam A. , Zhu, Valerie, Gerber, William K , Suzuki, Sakiko , Barker, Charlotte, Hutchinson, Lloyd, Khedr, Salwa, Cachia, David , Mangaonkar, Abhishek A. , McGuiness, Matthew, Higgins, Anne W. , Miron, Patricia M., Gerber, Jonathan M., Patel, Shyam A , Hutchinson, Lloyd, Khedr, Salwa , Miron, Patricia Minehart , Gerber, Jonathan M.

Mayo Clinic

American Journal of Hematology | May 20, 2026 | Volume: 101 | Issue: 8 | Pages: 1915-1927

10.1002/ajh.70374 | PMID 42157378 Get It

ABSTRACT Age‐related changes in human hematopoietic stem cells (HSCs) often form the basis for clonal hematopoiesis (CH), which presages the development of overt myeloid neoplasm with variable risk. CH can also arise after exposure to chemotherapy, radiotherapy, or immune interventions. In this study, we performed clinico‐genomic profiling of therapy‐related CH (t‐CH) ( n = 67) versus de novo CH ( n = 123) from a multidisciplinary CHIP Clinic. The most enriched mutations in t‐CH were TET2 (26.2%), DNMT3A (22.4%), and TP53 (8.4%). Median latency period from the time of initial exposure to the diagnosis of t‐CH was 6.96 ± 1.10 years. Patients with t‐CH had inferior event‐free survival compared to de novo CH (median 29.9 months versus 122.1 months, p = 0.0045). Overall survival was also shorter in t‐CH versus de novo CH (median 55.3 months vs. 129.2 months, p = 0.043). Genes that imparted significantly increased risk for progression from t‐CH to overt therapy‐related myeloid neoplasm (t‐MN) included JAK2 (relative risk (RR) 9.42, p = 0.0001), RUNX1 (RR 7.11, p = 0.001), EZH2 (RR 7.11, p = 0.001), and TET2 (RR 13.4, p = 0.01). Clonal dynamic modeling of patients with t‐CH who progressed to overt t‐MN showed an increase in the relative clonal fraction and new clonal outgrowth. In the t‐CH cohort, higher mean variant allele frequency was observed in progressors versus non‐progressors (77.1% vs. 30.6%, p = 0.017). This study sheds light onto outcomes for CH based on differing clinical ontogeny and has implications for previvorship for secondary malignancies.
C104-06 The National Institutes of Health (NIH) Multicenter Safety and Durability of Sirolimus for Lymphangioleiomyomatosis (LAM) (MIDAS) Registry: Real-World Safety and Efficacy of Sirolimus in Lymphangioleiomyomatosis
Darkwah, O A, Gupta, N, McMahan, S, Baker, R, Dilling, D F, Burger, C D, Henske, E, Girod, C E, Ruoss, S J, Veeraraghavan, S, Downey, G P, Koslow, M, Young, L R, Hewlett, J C, Han, M K, Shifren, A, Kotloff, R M, Kreider, M, Strange, C, Barker, A F, Pappas, G P, Morgan, M M, Paine, R, Estrada-Y-Martin, R M, Baqir, M, Parambil, J G, Szczesniak, R, McCormack, F X, Darkwah, Oliveira A G, McMahan, S, Baker, R, Dilling, Daniel F. , Girod, C, Ruoss, Stephen J. , Downey, Gregory P. , Koslow, Matthew , Young, Lisa R. , Hewlett, Justin C. , Han, MeiLan King , Shifren, Adrian , Kotloff, Robert M., Kreider, M., Strange, C, Barker, Amos, Pappas, G.P., Estrada-Y-Martin, Rosa Maria , Baqir, M., Parambil, Joseph G. , Szczesniak, R., McCormack, Francis X.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2824 Get It

Abstract Rationale Lymphangioleiomyomatosis (LAM) is a rare, progressive, cystic lung disease affecting women. Sirolimus has been shown to stabilize lung function in women with LAM, but real-world data on long-term safety and efficacy are limited. Methods The NIH Multicenter Safety and Durability of Sirolimus for LAM (MIDAS, NCT02432560) observational registry was launched in 2015. All adult (≥18 years) women with LAM (treated or untreated) were eligible to enroll at any of the 20 U.S. sites and followed longitudinally with serial assessments of lung function, health-related quality of life, and treatment related adverse event (TRAEs). Baseline cohort characteristics and TRAEs are summarized using descriptive analyses. Marginal structural models (MSMs) with inverse probability of treatment weighting estimated the causal effect of sirolimus on annualized forced expiratory volume in one-second (FEV1) decline, adjusting for age at LAM diagnosis, prior treatment with sirolimus, menopausal status, race, presence of angiomyolipomas, supplemental oxygen use; time-varying covariates included diffusing capacity for carbon monoxide (DLCO) and serum vascular endothelial growth factor-D (VEGF-D) levels. Results Longitudinal data was available in 350 LAM patients, most of whom (246, 70.3%) had sporadic LAM. The median age at the baseline pulmonary function test (PFT) measurement was 46 years (range: 19 - 74) and the median (IQR) number of serial PFTs obtained per patient was 3 (1 - 5). The average follow-up duration per patient was 2.8 years. Over half of the patients (196, 56%) were treated with sirolimus during the MIDAS observation period for a median (IQR) treatment duration of 4.9 (2.4 - 7.5) years. MSM analysis demonstrated that sirolimus treatment was durably effective and reduced FEV₁ decline by 74.36 mL/year (95% CI: 15.87 - 132.85) compared with no treatment (-85.31 mL/year for the untreated group vs. -10.95 mL/year for the treated group, p = 0.01). Sirolimus was generally well tolerated; treatment interruption ≥3 months was observed in 38 (19.4%) of the 196 sirolimus treated patients. Logistic regression analysis showed that higher levels of FEV1 (odds ratio: OR = 3.12 [1.45 - 7.11], p = 0.005), VEGF-D (OR = 1.0007 [1.0004 - 1.001], p &lt; 0.001), and DLCO (OR = 1.023 [1.0053 - 1.0413, p = 0.01]), were associated with treatment interruption. Conclusions In the MIDAS cohort, sirolimus treatment resulted in durable stabilization of lung function with a favorable safety profile over a 5-year period. These real-world data support sirolimus as a chronic suppressive therapy for LAM, demonstrating durable efficacy in slowing lung disease progression and tolerability with long-term use. This abstract is funded by: National Institutes of Health
Detecting healthcare-associated transmission and antifungal resistance in Candida auris via whole genome sequencing
Murphy, Shannon G. , Ross, Tracy R., Fitzgerald, Anna, Gauthier, Nick P.G. , Keller, Eric N., Barker, Erin, Memon, Warda, Moore, Terence, Curless, Melanie S., Maragakis, Lisa L. , Simner, Patricia J., Zhang, S., Fabre, Valeria , Simner, Patricia J , Zhang, Sean X , Murphy, Shannon G. , Ross, Tracy L., Fitzgerald, Anna, Chorlton, Samuel D. , Fabre, Valeria , Simner, Patricia J.

Mayo Clinic

Journal of Clinical Microbiology | March 25, 2026 | Volume: 64 | Issue: 5 | Pages: No page available

10.1128/jcm.01348-25 | PMID 41879325 Get It

ABSTRACT Candida auris is an emerging pathogen known for causing invasive, multidrug-resistant infections and healthcare-associated outbreaks. Measuring the relatedness of C. auris strains is critical for detecting and preventing healthcare-associated transmission. Whole genome sequencing (WGS) and analysis of single-nucleotide polymorphisms (SNPs) offer high-resolution assessments of genetic relatedness and antifungal susceptibility; however, interpretation requires an understanding of inter- and intra-patient C. auris diversity and genotypic markers of resistance, respectively. This study aimed to define SNP thresholds for assessing C. auris relatedness in healthcare-associated outbreak investigations, predict antifungal resistance via genotypic markers, and evaluate patient risk factors to inform future surveillance strategies. WGS was performed on 68 C. auris isolates (clades I and III) obtained from 31 hospitalized patients across a healthcare system between 2021 and 2024. Using MycoSNP analysis, we observed a maximum intra-patient variation of 14 SNPs. Five probable transmission clusters were identified based on epidemiologic links, with patient isolates differing by a median of 5 SNPs (range: 0−12). Analysis with a commercial pipeline (refMLST, BugSeq) showed similar clustering patterns. All new detections occurring more than 1 month after admission were linked to a cluster, representing a highly specific indicator of healthcare-associated infection. WGS detected known genotypic markers for fluconazole (ERG11 Y132F, F126L, and MRR1 N647T) and micafungin (FKS1 F635C) resistance, with the latter emerging during antimicrobial therapy. In addition, putative FUR1 mutations (G207R and Q16::STOP) associated with flucytosine resistance were identified. These findings emphasize the utility of WGS for identifying healthcare-associated clusters of C. auris and predicting antifungal resistance. IMPORTANCE Candida auris is a difficult-to-treat yeast that causes invasive infections in vulnerable patient populations. Healthcare exposure is a key risk factor for becoming colonized or infected with C. auris , and infection prevention groups focus on curbing the spread of this organism within the healthcare environment. Whole genome sequencing approaches are key for supporting these efforts, as they can help define clusters of C. auris transmission and can also provide insight into antifungal resistance. Our work provides practical guidance for interpreting genomic data in this setting, helping infection prevention teams respond more effectively to outbreaks and expanding the use of genotypic predictions for antifungal resistance.
Factors associated with severe neurological sequelae of COVID-19: findings from the multicenter COVID-BRAIN imaging cohort
Silva, Ana Isabel, Byrne, Keenan, Pollak, Lauren, Gundry, Katherine , Manousakis, Georgios , Metzler, Abby, Lenglet, Christophe , Eberly, Lynn E. , Kendall-Thomas, June, Kantarci, Orhun H. , Yaşar, Sevil , Ashizawa, Tetsuo , Kantarci, Kejal, Ratai, Eva‐Maria , Öz, Gülin , Lorente, Alfredo, Thotland, Jeromy, Lavallee, Jaime, Park, Young Bin, Li, Xiufeng, Atik, Merve, Senjem, Matthew L., Juttukonda, Meher R. , Salat, David H. , Sherman, Janet C. , Harrold, G. Kyle, Nabi, Mehreen, Rehman, Sana, Özdemir, Ipek, Senapati, Dillip, Barker, Peter B. , Karmonik, Christof , Gillani, Syed Asad Ali, Flores, Valerie, Davis, Rachel, Silva, Ana Isabel , Eberly, Lynn E. , Öz, Gülin , Kendall‐Thomas, June, Zeydan, Burcu , Mukerji, Shibani S. , Kantarci, Kejal , Joers, James M. , Lorente, Alfredo, Deelchand, Dinesh K. , Atık, Merve, Senjem, Matthew L. , Harrold, G. Kyle , Rehman, Sana , Senapati, Dillip K. , Gillani, Syed A., Davis, Rachel, Metzler, Abby

Mayo Clinic

Frontiers in Human Neuroscience | March 19, 2026 | Volume: 20 | Issue: No issue available | Pages: No page available

10.3389/fnhum.2026.1754342 | PMID 41939224 Get It

Introduction Neurological post-acute sequelae of COVID-19 (neuroPASC) are associated with persistent cognitive dysfunction and quality-of-life decline. We aimed to identify clinical, behavioral and sociodemographic factors associated with neuroPASC symptom burden two years after COVID-19 among individuals without prior neurological disease. Methods In this prospective, observational study, individuals with neuroPASC ( n = 102) and controls without symptomatic COVID-19 ( n = 74), all without prior neurological, psychiatric, or post-viral conditions, were enrolled between February 2022 and June 2024 across five academic sites. An unsupervised algorithm identified clusters with differing self-reported neurological symptom burden within the neuroPASC group. Functional differences between clusters were evaluated using quality-of-life, neurological and cognitive evaluations. Demographics, behavioral history, comorbidities, and blood biomarkers were compared across clusters and controls. Multivariable logistic regression assessed predictors of neuroPASC severity, including demographics, body-mass-index, Charlson Comorbidity Index, Framingham Risk Score, pre-existing endocrine/metabolic and/or gastrointestinal/hepatobiliary conditions, COVID-19 vaccination prior to infection, hospitalization during acute infection, and cumulative alcohol use. Results Two clusters emerged based on neurological symptom burden, labeled “high-burden” and “low-burden” neuroPASC, reflecting differences in the number and frequency of symptoms. Both clusters had deficits in quality-of-life and cognitive function compared to controls, with greater impairment in high-burden than low-burden neuroPASC. The clusters did not differ by sex, education, tobacco and cannabis use, blood pressure, body-mass-index, HbA1C, days since infection, hospitalization during COVID-19, pre-COVID vaccination rate, antibody-positivity, inflammation, and neurodegeneration biomarkers. The high-burden cluster was older and exhibited higher comorbidity burden and greater cumulative alcohol use compared with the low-burden cluster and controls. Pre-existing endocrine/metabolic and gastrointestinal/hepatobiliary conditions were more common in high-burden (63%) than in low-burden neuroPASC (35%). After adjusting for clinical and demographic factors, these pre-existing conditions remained the only independent predictor of severity, conferring a 3.5-fold increase in the odds of high-burden versus low-burden neuroPASC. Discussion Older age, higher comorbidity burden, greater cumulative alcohol use, and endocrine/metabolic and gastrointestinal conditions, rather than acute COVID-19 severity, were observed in the high-burden neuroPASC cluster. After multivariable adjustment, only pre-existing endocrine/metabolic and/or gastrointestinal/hepatobiliary conditions remained independently associated with high-burden neuroPASC, conferring a 3.5-fold increase in odds and highlighting the need for targeted post-infection monitoring in at-risk patients.
Utilization of bone modifying agents in metastatic hormone resistant prostate cancer: A retrospective study of real world patients.
Chohan, Yashveer, Ganadily, Naif A., Barker, Kenneth, Oberoi, Japneet Kaur , Afzal, M. , Tran, Phu N. , Orme, Jacob J. , Basu, Arnab, Kase, Adam M. , Heath, Elisabeth I. , Cobran, Ewan Kemar, Singh, Parminder, Barker, Kenneth N. , Childs, Daniel S. , Bryce, Alan H. , Cobran, Ewan K. , Singh, Parminder Pal , Zakharia, Yousef , Riaz, Irbaz Bin

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 127-127

10.1200/jco.2026.44.7_suppl.127 Get It

127 Background: Bone metastases affect up to 90 % of patients with metastatic hormone-resistant prostate cancer (mHRPC) and cause substantial morbidity from skeletal-related events (SREs) such as fracture, spinal-cord compression, and palliative interventions. Bone-modifying agents (BMAs) including bisphosphonates and denosumab reduce SRE risk and are NCCN-recommended, however, real-world use remains inconsistent. Methods: Patients with mHRPC treated from January 2017-September 2024 across Mayo Clinic sites were identified using SQL-based EHR queries confirmed by manual chart review. Bone Metastases were detected through keyword searchers of radiology reports and confirmed through manual chart review. SRE-prevention dosing was defined as zoledronic acid 4mg IV or denosumab 120mg SC; osteoporosis dosing was excluded. SREs were identified using diagnosis codes and text-pattern searches for radiotherapy, surgery, fracture, and spinal-cord compression. Descriptive statistics summarized BMA utilization and SRE incidence. Categorical variables were compared using Chi-square tests, and a risk ratio (RR) with 95% confidence intervals was calculated to evaluate association between early BMA initiation and SRE risk. Results: Among 778 patients with mHRPC, 685 (88 %) had bone metastases (mean age 70.5 years). Of these, 169 (24.7 %) had an SRE, and 261 (38.1 %) received BMAs at SRE-prevention doses (denosumab n = 157 [60 %]; zoledronic acid n = 104 [40 %]). Based on a chi-square test, combined SRE incidence did not differ significantly (No BMA 23 %, denosumab 23 %, zoledronic 33 %; p = 0.069). Bone pain at baseline was more common in patients who later received a BMA (136 [68 %]) than in those who did not (82 [41 %]; p < 0.001). Among 200 randomly sampled non-BMA patients, 83 had no recorded BMA discussion (66 also lacked bone pain), 38 lacked dental clearance, 32 had uncompleted plans and 18 declined therapy. Early BMA initiation (before first bone metastases) was associated with fewer SREs (16 % vs 29 %; RR 0.56, 95 % CI 0.33–0.96). Conclusions: Less than half of bone-metastatic mHRPC patients received BMAs. Non-initiation was often linked to modifiable factors such as delayed dental clearance or lack of treatment discussions, highlighting the need for system-level strategies to improve timely bone-directed care. SREs were common, affecting one quarter of patients. Small sample size precluded meaningful comparison of the impact of BMAs on SRE incidence however early BMA initiation may lower SREs. Incidence of SREs stratified by no BMA vs BMA treatment. SRE No BMA BMA Overall Pathological Fracture 6.4% (27/424) 4.9% (13/261) 5.8% (40/685) Radiotherapy to Bone 13.9% (59/424) 18.8% (49/261) 15.7% (108/685) Spinal Cord Compression 0.7% (3/424) 3.1% (8/261) 1.6% (11/685) Surgery to Bone 2.1% (9/424) 0.3% (1/261) 1.5% (10/685) Combined 23% (98/424) 27.2% (71/261) 24.7% (169/685)